Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A "Window of Opportunity" Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy

NCT02462538 is registered in ClinicalTrials.gov with Arbeitsgemeinschaft medikamentoese Tumortherapie as lead sponsor.

NCT NCT02462538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02462538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A "Window of Opportunity" Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase
Phase 1/2
Overall status
Terminated
Start date
November 3, 2015
Completion date
November 3, 2021
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk+ anaplastic large cell lymphoma